EFPIA

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Laying a new path for orphan drugs

Important changes in the way that the EU deals with orphan medicines could be signalled later this year when the European Commission publishes a revised version of its 2003 Communication (policy paper) on the topic
You need to be a subscriber to read this article.
Click here to find out more.

To go or not to go: the question the UK must answer

The prospect of the UK voting on 23 June to leave the European Union is a cause for deep concern among companies in the pharmaceutical sector
Regulatory

EU pharma associations seek orphan drug reform

One key issue is the need to demonstrate that an orphan medicine has a significant benefit over existing treatments
Regulatory

EFPIA says dedicated facilities not needed if EMA cross-contamination guidance works

Comments on a draft European Medicines Agency (EMA) guideline on setting health-based exposure limits for assessing the risk of manufacturing different medicinal products in shared facilities
Regulatory

Pharma associations take action over national European off-label authorisation laws

They could be a disincentive to pharma companies developing drugs for rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

EU celebrates 50 years of pharmaceutical legislation

<i>Manufacturing Chemist</i> asked public health organisations, industry and the academic community for their views on half a century of EU pharmaceutical legislation. The responses suggest that some organisations believe that it is far from perfect
Regulatory

European industry associations seek international co-ordination on cocrystal regulation

Salts and cocrystals can equally be accepted as drug substances
Subscribe now